Ana M Gutierrez-Colina1, Aimee W Smith1, Constance A Mara1, Avani C Modi2. 1. Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, United States. 2. Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, United States. Electronic address: Avani.modi@cchmc.org.
Abstract
OBJECTIVE: The objectives of this study were to examine the continuity of adherence barriers across stages of development in pediatric epilepsy and to assess the differential influence of barriers on several important clinical outcomes from early childhood to young adulthood, including adherence, seizures, and health-related quality of life (HRQOL). METHOD: A developmentally representative sample of youth 2-25years with epilepsy was obtained by combining data from five different studies. A total of 269 caregivers and 77 adolescents and young adults were included in this investigation. Participants completed measures of adherence barriers and HRQOL. An electronic monitoring system was used to assess adherence to the primary antiepileptic drug over 30days. The prevalence of individual barriers across development and their relative importance as predictors of clinical outcomes were examined. RESULTS: Adherence barriers are characterized by both continuity and discontinuity from early childhood to early adulthood. Barriers such as disliking the taste of medication, parent forgetfulness, and refusal to take medications were significantly more salient during certain developmental periods. No significant differences across age groups were found for other barriers, including difficulty getting to the pharmacy and embarrassment. Certain adherence barriers, such as running out of medications, were more important to particular clinical outcomes despite being low prevalence. Adherence barriers differentially predicted adherence, seizure control, and HRQOL based on developmental stage. CONCLUSION: Routine assessment of adherence barriers is imperative from toddlerhood to young adulthood given that the prevalence of barriers and their relative influence on important health outcomes vary by developmental stage. Adherence intervention efforts should be targeted, developmentally tailored, and focused on those barriers that are most predictive of poor outcomes for a given developmental period.
OBJECTIVE: The objectives of this study were to examine the continuity of adherence barriers across stages of development in pediatric epilepsy and to assess the differential influence of barriers on several important clinical outcomes from early childhood to young adulthood, including adherence, seizures, and health-related quality of life (HRQOL). METHOD: A developmentally representative sample of youth 2-25years with epilepsy was obtained by combining data from five different studies. A total of 269 caregivers and 77 adolescents and young adults were included in this investigation. Participants completed measures of adherence barriers and HRQOL. An electronic monitoring system was used to assess adherence to the primary antiepileptic drug over 30days. The prevalence of individual barriers across development and their relative importance as predictors of clinical outcomes were examined. RESULTS:Adherence barriers are characterized by both continuity and discontinuity from early childhood to early adulthood. Barriers such as disliking the taste of medication, parent forgetfulness, and refusal to take medications were significantly more salient during certain developmental periods. No significant differences across age groups were found for other barriers, including difficulty getting to the pharmacy and embarrassment. Certain adherence barriers, such as running out of medications, were more important to particular clinical outcomes despite being low prevalence. Adherence barriers differentially predicted adherence, seizure control, and HRQOL based on developmental stage. CONCLUSION: Routine assessment of adherence barriers is imperative from toddlerhood to young adulthood given that the prevalence of barriers and their relative influence on important health outcomes vary by developmental stage. Adherence intervention efforts should be targeted, developmentally tailored, and focused on those barriers that are most predictive of poor outcomes for a given developmental period.
Authors: Rachelle R Ramsey; Kristin Loiselle; Joseph R Rausch; Jordan Harrison; Avani C Modi Journal: Epilepsy Behav Date: 2016-03-12 Impact factor: 2.937
Authors: Samuel Waller Terman; Wesley T Kerr; Carole E Aubert; Chloe E Hill; Zachary A Marcum; James F Burke Journal: Neurology Date: 2021-12-10 Impact factor: 9.910
Authors: Charles D Varnell; Kristin L Rich; Avani C Modi; David K Hooper; Mark H Eckman Journal: Am J Kidney Dis Date: 2022-02-25 Impact factor: 11.072
Authors: Charles D Varnell; Kristin L Rich; Bin Zhang; Adam C Carle; Ahna L H Pai; Avani C Modi; David K Hooper Journal: Pediatr Nephrol Date: 2021-01-27 Impact factor: 3.651
Authors: Onengiya Harry; Lori E Crosby; Constance Mara; Tracy V Ting; Jennifer L Huggins; Avani C Modi Journal: Pediatr Rheumatol Online J Date: 2020-04-26 Impact factor: 3.054
Authors: Dana M Bakula; Katherine W Junger; Shanna M Guilfoyle; Constance A Mara; Avani C Modi Journal: Epilepsia Date: 2022-06-03 Impact factor: 6.740